{
  "docId": "019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "docSlug": "f1da613c1103b289ca26ebdf1a360ae4",
  "documentTitle": "Alkermes | Results Presentation Deck | 21 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 21,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a two-stage clinical development strategy with specific objectives and assessment criteria for each phase.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a86b-72ae-acf4-09eb2fd3a18a/17",
  "deckHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a",
  "deckJsonHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a.json",
  "deckAnchorHref": "/decks/019de074-a86b-72ae-acf4-09eb2fd3a18a#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.225
      },
      "kind": "list",
      "text": "Phase 1b Proof-of-Concept (POC) Study: Objective: Early POC data + dose range estimation for phase 2. Key Assessments: EEG-based maintenance of wakefulness test, drug exposure, safety/tolerability. Timeline: Initiation Q2 2023, data by year-end.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fead5ed-ec90-4700-ab7a-49517b0545b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.225
      },
      "kind": "list",
      "text": "Phase 1 First-in-Human (FIH) Studies: Objective: Measure and model pharmacokinetics (PK)/pharmacodynamics (PD) and evaluate safety and tolerability of single and multiple ascending doses. Key Assessments: Drug exposure, safety/tolerability, target engagement (qEEG).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7014b7dd-ead0-4ec1-bd1d-13c0cfa7ad9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "EEG: electroencephalogram; qEEG: quantitative electroencephalogram",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3995e0ad-d461-49be-87b6-6b436e6d66b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680 Clinical Development Plan Targeting Clinical Proof-of-Concept Data by Year-End 2023",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ca5e0ea-48e3-41ff-a65b-c6cf52473c5b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 17,
      "from": 15,
      "beatId": "1abdc999-2841-4c49-9bdd-97e3feb9fb1c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck provides clear priorities, oncology business separation updates, and clinical development plan, satisfying the need for updates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 17,
      "from": 15,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "bb2f89f1-4583-4873-95d9-04c800aded6b",
      "evidence": "The deck emphasizes the need for clear priorities and updates on the oncology business separation.",
      "position": 0,
      "objective": "Highlighting the importance of clear priorities and oncology business separation updates",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}